<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02918357</url>
  </required_header>
  <id_info>
    <org_study_id>165510</org_study_id>
    <secondary_id>NCI-2018-00039</secondary_id>
    <nct_id>NCT02918357</nct_id>
  </id_info>
  <brief_title>Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence</brief_title>
  <acronym>PSMA BCR</acronym>
  <official_title>Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are imaging patients with prostate cancer using a new PET imaging agent
      (Ga-68-PSMA-11) in order to evaluate it's ability to detection prostate cancer in patients
      with biochemical recurrence after prostatectomy and radiation therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Imaging and staging of prostate cancer is critical for surgical and treatment planning.
      Patients with suspected metastatic prostate cancer will be imaged using Gallium-68 labeled
      PSMA-11 in order to demonstrate its utility. The investigators plan to utilize this data to
      obtain further approvals of the Ga-68-PSMA-11 compound, so that this agent will become
      available for clinical imaging in prostate cancer patients. In the biochemical recurrence
      population, the primary objective is to determine the sensitivity and positive predictive
      value (PPV) on a per-patient and per-region-basis of 68Ga-PSMA-11 PET for detection of tumor
      location confirmed by histopathology/biopsy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2016</start_date>
  <completion_date type="Actual">September 21, 2017</completion_date>
  <primary_completion_date type="Actual">September 21, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation</measure>
    <time_frame>1 month</time_frame>
    <description>PPVs were calculated across the group on a per-patient basis on 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and reported along with the corresponding two-sided 95% confidence intervals (CI). The CIs were constructed using the Wilson score method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation</measure>
    <time_frame>1 month</time_frame>
    <description>PPVs were calculated across the group on a per-region-basis on 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and reported along with the corresponding two-sided 95% CIs. The CIs were constructed using the Wilson score method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up</measure>
    <time_frame>1 month</time_frame>
    <description>PPVs on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by conventional imaging follow-up were calculated and reported along with the corresponding two-sided 95% CI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up</measure>
    <time_frame>1 month</time_frame>
    <description>PPVs on a per-region-basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and conventional imaging follow-up were calculated and reported along with the corresponding two-sided 95% CI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity on a Per-patient Basis</measure>
    <time_frame>1 month</time_frame>
    <description>Sensitivity, on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy was calculated. The 95% CI was calculated using the Wilson score method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity on a Per-region Basis</measure>
    <time_frame>1 month</time_frame>
    <description>Sensitivity, on a per-region basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy was calculated. The 95% CI was calculated using the Wilson score method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value</measure>
    <time_frame>1 month</time_frame>
    <description>Detection rate was defined as proportion of 68Ga-PSMA-11 PET positive patients, independent of the reference standard stratified by PSA value (0.2-&lt;0.5; 0.5-&lt;1.0; 1.0-&lt;2.0; 2.0-&lt;5.0, and ≥5.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter-reader Agreement Per-region</measure>
    <time_frame>1 month</time_frame>
    <description>Inter-reader reproducibility for positivity at region level was reported using the Fleiss' Kappa test for multiple readers. Kappa value varies from 0 (no agreement) to 1 (perfect agreement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Change in Clinical Management</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Clinical management changes were assessed using surveys of Intended Management to determine the percent change in clinical management after 68Ga-PSMA-11 PET.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment - Heart Rate</measure>
    <time_frame>1 day</time_frame>
    <description>Patient vital signs were measured before and after 68Ga-PSMA-11 injections and absolute mean change was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment - Blood Pressure</measure>
    <time_frame>1 day</time_frame>
    <description>Patient vital signs were measured before and after 68Ga-PSMA-11 injections and absolute mean change was calculated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">385</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Ga-68 labeled PSMA-11 PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ga-68 labeled PSMA-11 PET</intervention_name>
    <description>Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.</description>
    <arm_group_label>Ga-68 labeled PSMA-11 PET</arm_group_label>
    <other_name>Ga-68 labeled DKFZ-PSMA-11</other_name>
    <other_name>Ga-68 labeled Glu-NH-CO-NH- Lys(Ahx)-HBED-CC</other_name>
    <other_name>Ga-68 labeled Glu-urea- Lys(Ahx)-HBED-CC</other_name>
    <other_name>Ga-68 labeled HBED-CC PSMA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathological proven prostate adenocarcinoma.

          -  Rising prostate-specific antigen (PSA) after definitive therapy with prostatectomy or
             radiation therapy (external beam or brachytherapy).

               -  Post radical prostatectomy (RP) - American Urological Association (AUA)
                  recommendation

                    -  PSA greater than 0.2 ng/mL measured more than 6 weeks after RP and,

                    -  Confirmatory persistent PSA greater than 0.2 ng/mL

               -  Post-radiation therapy -ASTRO-Phoenix consensus definition

                    -  Nadir + greater than or equal to 2 ng/mL rise in PSA

          -  Karnofsky performance status of greater than 50 (or Eastern Cooperative Oncology Group
             (ECOG) /World Health Organization (WHO) equivalent).

          -  Age &gt; 18.

          -  Ability to understand a written informed consent document, and the willingness to sign
             it.

        Exclusion Criteria:

          -  Investigational therapy for prostate cancer.

          -  Unable to lie flat, still or tolerate a PET scan.

          -  Prior history of any other malignancy within the last 2 years, other than skin basal
             cell or cutaneous superficial squamous cell carcinoma that has not metastasized and
             superficial bladder cancer.

          -  Contraindication to furosemide administration including prior allergy or adverse
             reaction to furosemide or sulfa drugs. (Note: This exclusion criteria can be removed
             if Furosemide is omitted as part of the PET imaging protocol if a second-generation
             scatter correction is available for the used PET device).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Hope, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <results_first_submitted>September 30, 2019</results_first_submitted>
  <results_first_submitted_qc>November 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 2, 2019</results_first_posted>
  <last_update_submitted>November 27, 2019</last_update_submitted>
  <last_update_submitted_qc>November 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Thomas Hope</investigator_full_name>
    <investigator_title>Assistant Professor of Radiology and Biomedical Imaging</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ga-68 Labeled PSMA-11 Positron Emission Tomography (PET)</title>
          <description>Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
Ga-68 labeled PSMA-11 PET: Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="385"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Investigational Drug Administration</title>
              <participants_list>
                <participants group_id="P1" count="385"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>PET/CT Scan</title>
              <participants_list>
                <participants group_id="P1" count="385"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="385"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ga-68 Labeled PSMA-11 PET</title>
          <description>PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
Ga-68 labeled PSMA-11 PET: Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="385"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" lower_limit="45" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American and Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Initial therapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Prostatectomy only</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Radiotherapy only</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Prostatectomy and Salvage Radiotherapy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation</title>
        <description>PPVs were calculated across the group on a per-patient basis on 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and reported along with the corresponding two-sided 95% confidence intervals (CI). The CIs were constructed using the Wilson score method.</description>
        <time_frame>1 month</time_frame>
        <population>All subjects who received a 68Ga-PSMA-11 injection, had their 68Ga-PSMA-11 scan independently and blindly interpreted on a per patient basis. Per patient analyses included an evaluation of positive or negative for presence of localized prostate cancer (PCa).</population>
        <group_list>
          <group group_id="O1">
            <title>Pet Positive (Per Patient)</title>
            <description>Evaluate the PPV on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation</title>
          <description>PPVs were calculated across the group on a per-patient basis on 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and reported along with the corresponding two-sided 95% confidence intervals (CI). The CIs were constructed using the Wilson score method.</description>
          <population>All subjects who received a 68Ga-PSMA-11 injection, had their 68Ga-PSMA-11 scan independently and blindly interpreted on a per patient basis. Per patient analyses included an evaluation of positive or negative for presence of localized prostate cancer (PCa).</population>
          <units>percentage of times value is true</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.84" upper_limit="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation</title>
        <description>PPVs were calculated across the group on a per-region-basis on 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and reported along with the corresponding two-sided 95% CIs. The CIs were constructed using the Wilson score method.</description>
        <time_frame>1 month</time_frame>
        <population>All subjects who received a 68Ga-PSMA-11 injection, had their 68Ga-PSMA-11 scan independently and blindly interpreted on a per region basis. Per region analyses included an evaluation of positive or negative for presence of PCa. Regional analyses included prostate bed, pelvic nodes, extrapelvic non-bone, and bone.</population>
        <group_list>
          <group group_id="O1">
            <title>Pet Positive (Per Region)</title>
            <description>Evaluate the PPV on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation</title>
          <description>PPVs were calculated across the group on a per-region-basis on 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and reported along with the corresponding two-sided 95% CIs. The CIs were constructed using the Wilson score method.</description>
          <population>All subjects who received a 68Ga-PSMA-11 injection, had their 68Ga-PSMA-11 scan independently and blindly interpreted on a per region basis. Per region analyses included an evaluation of positive or negative for presence of PCa. Regional analyses included prostate bed, pelvic nodes, extrapelvic non-bone, and bone.</population>
          <units>percentage of times value is true</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" lower_limit="0.85" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up</title>
        <description>PPVs on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by conventional imaging follow-up were calculated and reported along with the corresponding two-sided 95% CI.</description>
        <time_frame>1 month</time_frame>
        <population>One hundred and twenty-five patients had confirmed imaging at follow-up for this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Pet Positive (Per Patient)</title>
            <description>Evaluate the PPV on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy</description>
          </group>
        </group_list>
        <measure>
          <title>PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up</title>
          <description>PPVs on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by conventional imaging follow-up were calculated and reported along with the corresponding two-sided 95% CI.</description>
          <population>One hundred and twenty-five patients had confirmed imaging at follow-up for this analysis</population>
          <units>percentage of times value is true</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.69" upper_limit="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up</title>
        <description>PPVs on a per-region-basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and conventional imaging follow-up were calculated and reported along with the corresponding two-sided 95% CI.</description>
        <time_frame>1 month</time_frame>
        <population>Two-hundred and forty-nine patients had confirmed regional imaging in follow up for this sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Pet Positive (Per Patient)</title>
            <description>Evaluate the PPV on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy</description>
          </group>
        </group_list>
        <measure>
          <title>PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up</title>
          <description>PPVs on a per-region-basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and conventional imaging follow-up were calculated and reported along with the corresponding two-sided 95% CI.</description>
          <population>Two-hundred and forty-nine patients had confirmed regional imaging in follow up for this sample.</population>
          <units>percentage of times value is true</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.88" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity on a Per-patient Basis</title>
        <description>Sensitivity, on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy was calculated. The 95% CI was calculated using the Wilson score method.</description>
        <time_frame>1 month</time_frame>
        <population>Seventy-nine patients had confirmed patient histopathology validation for this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Ga-68 Labeled PSMA-11 PET</title>
            <description>PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
Ga-68 labeled PSMA-11 PET: Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity on a Per-patient Basis</title>
          <description>Sensitivity, on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy was calculated. The 95% CI was calculated using the Wilson score method.</description>
          <population>Seventy-nine patients had confirmed patient histopathology validation for this analysis</population>
          <units>percentage of sensitivity</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.84" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity on a Per-region Basis</title>
        <description>Sensitivity, on a per-region basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy was calculated. The 95% CI was calculated using the Wilson score method.</description>
        <time_frame>1 month</time_frame>
        <population>Eighty-four patients had confirmed histopathology region validation for this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Ga-68 Labeled PSMA-11 PET</title>
            <description>PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
Ga-68 labeled PSMA-11 PET: Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity on a Per-region Basis</title>
          <description>Sensitivity, on a per-region basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy was calculated. The 95% CI was calculated using the Wilson score method.</description>
          <population>Eighty-four patients had confirmed histopathology region validation for this analysis</population>
          <units>percentage of sensitivity</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.82" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value</title>
        <description>Detection rate was defined as proportion of 68Ga-PSMA-11 PET positive patients, independent of the reference standard stratified by PSA value (0.2-&lt;0.5; 0.5-&lt;1.0; 1.0-&lt;2.0; 2.0-&lt;5.0, and ≥5.0).</description>
        <time_frame>1 month</time_frame>
        <population>Portion of patients with 68Ga-PSMA-11 PET positive findings were stratified by PSA range and disease location in accordance with Prostate Magnetic Resonance Imaging Study (PROMIS)</population>
        <group_list>
          <group group_id="O1">
            <title>PSA &lt;0.5</title>
            <description>Patients whom have a PSA nadir value of &lt;0.5</description>
          </group>
          <group group_id="O2">
            <title>PSA 0.5 - &lt;1.0</title>
            <description>Patients whom have a PSA nadir value of 0.5 to &lt;1.0</description>
          </group>
          <group group_id="O3">
            <title>PSA 1.0 - &lt;2.0</title>
            <description>Patients whom have a PSA nadir value of 1.0 to &lt;2.0</description>
          </group>
          <group group_id="O4">
            <title>PSA 2.0 - &lt;5.0</title>
            <description>Patients whom have a PSA nadir value of 2.0 - &lt;5.0</description>
          </group>
          <group group_id="O5">
            <title>PSA ≥5.0</title>
            <description>Patients whom have a PSA nadir value of ≥5.0</description>
          </group>
        </group_list>
        <measure>
          <title>Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value</title>
          <description>Detection rate was defined as proportion of 68Ga-PSMA-11 PET positive patients, independent of the reference standard stratified by PSA value (0.2-&lt;0.5; 0.5-&lt;1.0; 1.0-&lt;2.0; 2.0-&lt;5.0, and ≥5.0).</description>
          <population>Portion of patients with 68Ga-PSMA-11 PET positive findings were stratified by PSA range and disease location in accordance with Prostate Magnetic Resonance Imaging Study (PROMIS)</population>
          <units>percentage detected</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="83"/>
                    <measurement group_id="O5" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inter-reader Agreement Per-region</title>
        <description>Inter-reader reproducibility for positivity at region level was reported using the Fleiss' Kappa test for multiple readers. Kappa value varies from 0 (no agreement) to 1 (perfect agreement).</description>
        <time_frame>1 month</time_frame>
        <population>Patients included in the analyses were scanned to include all regions under review</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Bed</title>
            <description>Patients who have the prostate bed included in their study scan</description>
          </group>
          <group group_id="O2">
            <title>Pelvic Nodes</title>
            <description>Patients who have the pelvic nodes included in their study scan</description>
          </group>
          <group group_id="O3">
            <title>Extrapelvic Soft Tissue</title>
            <description>Patients who have the extrapelvic soft tissue included in their study scan</description>
          </group>
          <group group_id="O4">
            <title>Bone</title>
            <description>Patients who have the pelvic bone included in their study scan</description>
          </group>
        </group_list>
        <measure>
          <title>Inter-reader Agreement Per-region</title>
          <description>Inter-reader reproducibility for positivity at region level was reported using the Fleiss' Kappa test for multiple readers. Kappa value varies from 0 (no agreement) to 1 (perfect agreement).</description>
          <population>Patients included in the analyses were scanned to include all regions under review</population>
          <units>kappa</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="385"/>
                <count group_id="O4" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="0.61" upper_limit="0.70"/>
                    <measurement group_id="O2" value="0.73" lower_limit="0.69" upper_limit="0.78"/>
                    <measurement group_id="O3" value="0.70" lower_limit="0.65" upper_limit="0.74"/>
                    <measurement group_id="O4" value="0.78" lower_limit="0.73" upper_limit="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Change in Clinical Management</title>
        <description>Clinical management changes were assessed using surveys of Intended Management to determine the percent change in clinical management after 68Ga-PSMA-11 PET.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ga-68 Labeled PSMA-11 PET</title>
            <description>Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Clinical Management</title>
          <description>Clinical management changes were assessed using surveys of Intended Management to determine the percent change in clinical management after 68Ga-PSMA-11 PET.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Assessment - Heart Rate</title>
        <description>Patient vital signs were measured before and after 68Ga-PSMA-11 injections and absolute mean change was calculated.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-Infusion Heart Rate</title>
            <description>All patients were assessed for safety measures that included Heart Rate before infusion</description>
          </group>
          <group group_id="O2">
            <title>Post-Infusion Heart Rate</title>
            <description>All patients were assessed for safety measures that included Heart Rate after infusion</description>
          </group>
          <group group_id="O3">
            <title>Absolute Change in Heart Rate</title>
            <description>All subjects had the absolute mean in heart rate calculated to assess for safety</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Assessment - Heart Rate</title>
          <description>Patient vital signs were measured before and after 68Ga-PSMA-11 injections and absolute mean change was calculated.</description>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8" spread="13.3"/>
                    <measurement group_id="O2" value="66.9" spread="13.6"/>
                    <measurement group_id="O3" value="0.9" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Assessment - Blood Pressure</title>
        <description>Patient vital signs were measured before and after 68Ga-PSMA-11 injections and absolute mean change was calculated.</description>
        <time_frame>1 day</time_frame>
        <population>Pressure exerted by a 1 millimeter vertical column of mercury (Hg) at 0 degree Celsius is defined as (mmHg)</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Injection</title>
            <description>All patients were assessed for safety measures that included blood pressure before infusion</description>
          </group>
          <group group_id="O2">
            <title>Post-Injection</title>
            <description>All patients were assessed for safety measures that included blood pressure after infusion</description>
          </group>
          <group group_id="O3">
            <title>Absolute Mean Change</title>
            <description>All subjects had the absolute mean in blood pressure calculated to assess for safety</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Assessment - Blood Pressure</title>
          <description>Patient vital signs were measured before and after 68Ga-PSMA-11 injections and absolute mean change was calculated.</description>
          <population>Pressure exerted by a 1 millimeter vertical column of mercury (Hg) at 0 degree Celsius is defined as (mmHg)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.8" spread="17.7"/>
                    <measurement group_id="O2" value="137.0" spread="17.4"/>
                    <measurement group_id="O3" value="1.0" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.3" spread="33.8"/>
                    <measurement group_id="O2" value="81.1" spread="10.6"/>
                    <measurement group_id="O3" value="0.6" spread="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were monitored for adverse events during and for 2 hours after radiotracer administration. Patients were also contacted by phone to assess for the development of delayed adverse events up to 24 hours after radiotracer administration.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ga-68 Labeled PSMA-11 PET</title>
          <description>PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
Ga-68 labeled PSMA-11 PET: Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="385"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="385"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="385"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Thomas Hope</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>(415) 221-4810 ext 2264</phone>
      <email>thomas.hope@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

